These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1527898)

  • 41. Effects of disopyramide on reperfusion arrhythmias in dogs.
    Chagnac A; Pelleg A; Belhassen B; Lubliner J; Vidné B; Laniado S
    J Cardiovasc Pharmacol; 1982; 4(6):994-8. PubMed ID: 6185794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model.
    Uprichard AC; Harron DW
    Br J Pharmacol; 1989 Jan; 96(1):220-6. PubMed ID: 2924074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction.
    Horowitz JD; Anavekar SN; Morris PM; Goble AJ; Doyle AE; Louis WJ
    J Cardiovasc Pharmacol; 1981; 3(3):409-19. PubMed ID: 6168823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Actions of disopyramide on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs during the late post-myocardial infarction phase.
    Cobbe SM; Hoffmann E; Ritzenhoff A; Brachmann J; Kübler W; Senges J
    Am J Cardiol; 1984 Jun; 53(11):1712-8. PubMed ID: 6731317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardioprotective effects of various class I antiarrhythmic drugs in canine hearts.
    Hanaki Y; Sugiyama S; Hieda N; Taki K; Hayashi H; Ozawa T
    J Am Coll Cardiol; 1989 Jul; 14(1):219-24. PubMed ID: 2738264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systolic time intervals in evaluation of the negative inotropic effect after single oral doses of mexiletine and disopyramide.
    Rousson D; Piolat C; Galleyrand J; Ferry S; Boissel JP
    Eur J Clin Pharmacol; 1986; 30(3):263-8. PubMed ID: 3732360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 2nd communication: effect on the peripheral nervous system and peripheral organs.
    Hirotsu I; Kihara T; Hattori Y; Hatta M; Hirose N; Ishihara T; Satoh F
    Arzneimittelforschung; 1988 Oct; 38(10):1410-7. PubMed ID: 3196381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of moricizine in malignant ventricular arrhythmias.
    Horowitz LN
    Am J Cardiol; 1990 Feb; 65(8):41D-46D; discussion 68D-71D. PubMed ID: 1689535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G; Lefkos N; Efthymiadis AP; Styliadis IG; Tsapas G
    Acta Cardiol; 1995; 50(2):125-34. PubMed ID: 7610735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemodynamic effects of moricizine at rest and during supine bicycle exercise: results in patients with ventricular tachycardia and left ventricular dysfunction.
    Seals AA; English L; Leon CA; Wierman AM; Young JB; Zoghbi W; Quinones MA; Mahler SA; Roberts R; Pratt CM
    Am Heart J; 1986 Jul; 112(1):36-43. PubMed ID: 3524172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. R56865, a potent new antiarrhythmic agent, effective during ischemia and reperfusion in the rat heart.
    Garner JA; Hearse DJ; Bernier M
    J Cardiovasc Pharmacol; 1990 Sep; 16(3):468-79. PubMed ID: 1700220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serial electrophysiological testing of antiarrhythmic drug efficacy in patients with recurrent ventricular tachycardia.
    Breithardt G; Seipel L; Abendroth RR; Loogen F
    Eur Heart J; 1980 Feb; 1(1):11-24. PubMed ID: 7026245
    [No Abstract]   [Full Text] [Related]  

  • 53. Cardioversion, defibrillation, and overdrive pacing of ventricular arrhythmias: the effect of moricizine in dogs with sustained monomorphic ventricular tachycardia.
    Avitall B; Hare J; Zander G; Lessila C; Dhala A; Deshpande S; Jazayeri M; Sra J; Akhtar M
    Pacing Clin Electrophysiol; 1993 Nov; 16(11):2092-7. PubMed ID: 7505920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Availability of electrophysiological approach to the selection and assessment of antiarrhythmic drugs for recurrent ventricular tachycardia.
    Kasanuki H; Ohnishi S; Hirosawa K
    Jpn Circ J; 1983 Jan; 47(1):105-23. PubMed ID: 6827769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation.
    Lerman BB; Waxman HL; Buxton AE; Josephson ME
    Am J Cardiol; 1983 Mar; 51(5):759-64. PubMed ID: 6829435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias.
    Whitford EG; McGovern B; Schoenfeld MH; Garan H; Newell JB; McElroy M; Ruskin JN
    Am Heart J; 1988 Feb; 115(2):360-6. PubMed ID: 3341170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias.
    Anderson JL
    Am J Cardiol; 1990 Feb; 65(8):32D-40D. PubMed ID: 2106254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of antiarrhythmic drugs on the repetitive extrasystole threshold and the ventricular fibrillation threshold.
    Murakawa Y; Toda I; Nozaki A; Kawakubo K; Sugimoto T
    Cardiology; 1989; 76(1):58-66. PubMed ID: 2468414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
    Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
    J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined application of class I antiarrhythmic drugs causes "additive", "reductive", or "synergistic" sodium channel block in cardiac muscles.
    Kawamura T; Kodama I; Toyama J; Hayashi H; Saito H; Yamada K
    Cardiovasc Res; 1990 Nov; 24(11):925-31. PubMed ID: 2176934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.